drugset
drugset / Trial / NCT01692145

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

NCT01692145 ↗

Phase 2 Completed Kissei Pharmaceutical Co., Ltd.
Parallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ozagrel Small molecule — Other

Indications

dry eye syndrome